To determine whether PD-CSF-CTCs could be used as a tool for functional analysis of therapeutic responses in LMD, as a proof of concept, we tested IGF1R as a drug target on the basis of our scRNA-seq data (Figure 2D). This evidence concerns the gene IGF1R and Langer mesomelic dysplasia.